Tirzepatide A dual-agonist peptide that targets both the GLP-1 and GIP pathways for compounded weight management at SSK Longevity in Newport Beach, California
Approved for liver condition MASH in 2025
Clinical trials have determined that tirzepatide is associated with certain rare but serious adverse events in some patients, including developing pancreatitis, gallbladder problems, diabetic retinopathy, serious allergic reactions, or acute kidney injury
Volume depends on concentration
The demand for weight loss solutions is at an all-time high globally
Here's what you actually need before picking one: what each option costs by plan length according to the brand's own pricing pages, who's really involved in prescribing and filling your medication, what happens if you want to cancel, and the handful of things worth confirming yourself before you start